Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mixed results for Boston Scientific:

This article was originally published in Clinica

Executive Summary

First-quarter sales for Boston Scientific rose by 9% to $470 million, although net income dropped to $67 million, compared with $75 million in the previous period. Excluding currency effects, sales rose by 13%. Peter Nicholas, chairman and CEO, said that the results were in line with expectations. The company conceded that it was disadvantaged by the fact that it had not yet obtained marketing approval for its NIR and Radius stents in the US and Japan, but said they were making progress.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT081294

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel